Skip to main content

Table 1 Baseline characteristics for patients in CCRT group vs. chemotherapy group

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

Characteristics CCRT (n = 55) Chemotherapy (n = 86) P
Sex 0.689
 Male 43 (78.2%) 64(74.4%)  
 Female 12 (21.8%) 22 (25.6%)  
Age, years 0.862
 ≤ 60 32 (58.2%) 48 (55.8%)  
 > 60 23 (41.8%) 38 (44.2%)  
Tumor location 0.674
 cervical 3 (5.5%) 3 (3.5%)  
 upper thoracic 16 (29.1%) 19 (22.1%)  
 middle thoracic 23 (41.8%) 38 (44.2%)  
 lower thoracic 13 (23.6%) 26 (30.2%)  
KPS score 0.467
 ≥ 80 45 (81.8%) 64(74.4%)  
 < 80 10 (18.2%) 22 (25.6%)  
T-stage 0.816
 T1–2 8 (14.5%) 15 (17.4%)  
 T3–4 47 (85.5%) 71 (82.6%)  
N-stage 0.797
 N0 6 (10.9%) 11 (12.8%)  
 N+ 49 (89.1%) 75 (87.2%)  
Dysphagia score 0.096
 0 (asymptomatic) 4 (7.3%) 5 (5.8%)  
 1 (eat solid diet with some dysphagia) 5 (9.1%) 23 (26.7%)  
 2 (eat semisolid diet) 28 (50.9%) 36 (41.9%)  
 3 (drink liquid diet) 13 (23.6%) 19 (22.1%)  
 4 (complete dysphagia) 5 (9.1%) 3 (3.5%)  
Number of metastatic organs 0.351
 Solitary metastasis 41 (74.5%) 57 (66.3%)  
 Multiple metastasis 14 (25.5%) 29 (33.7%)  
Metastasis sites  
 Nonregional lymph nodes 14 (25.5%) 24 (27.9%) 0.831
 lung 14 (25.5%) 16 (18.6%)  
 liver 17 (30.9%) 34 (39.5%)  
 bone 21 (38.2%) 36 (41.9%)  
 others 5 (9.1%) 8 (9.3%)  
Chemotherapy regimens
 PTX + DDP 24 (43.6%) 42 (48.8%) 0.605
 5-Fu + DDP 31 (56.4%) 44 (51.2%)  
Chemotherapy cycles 0.585
 > 2 20 (36.4%) 27 (31.4%)  
 ≤ 2 35 (63.6%) 59 (68.6%)  
  1. Abbreviations: CCRT concurrent chemoradiotherapy, KPS Karnofsky Performance Status, CDDP cisplatin, 5-FU 5-fluorouracil, PTX paclitaxel